Icon Plc  (ICLR)
Other Ticker:  
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
Price: $306.0000 $-6.39 -2.046%
Day's High: $311.39 Week Perf: -4.66 %
Day's Low: $ 305.43 30 Day Perf: -7.94 %
Volume (M): 394 52 Wk High: $ 344.77
Volume (M$): $ 120,472 52 Wk Avg: $257.92
Open: $309.32 52 Wk Low: $181.92

 Market Capitalization (Millions $) 25,312
 Shares Outstanding (Millions) 83
 Employees 15,950
 Revenues (TTM) (Millions $) 8,120
 Net Income (TTM) (Millions $) 1,237
 Cash Flow (TTM) (Millions $) 89
 Capital Exp. (TTM) (Millions $) 141

Icon Plc
Icon Plc is a global provider of clinical trials and consulting services that has been in operation since 1990. The company is headquartered in Dublin, Ireland, and operates multiple offices and laboratories across North America, Europe, and Asia-Pacific. Icon Plc is well known for its expertise in drug development, innovative technology solutions, and analytical and laboratory services.

Clinical trials are the primary focus of Icon Plc. The company offers drug development, clinical and medical affairs, patient and site engagement, and data management services to support various stages of clinical trials. Icon Plc has experience in numerous therapeutic areas, such as oncology, neurology, cardiovascular diseases, infectious diseases, and immunology, among others. The company's main goal is to accelerate clinical development timelines, reduce operational costs and provide superior data integrity to support sponsors' and healthcare providers' decisions.

Icon Plc also provides consulting services, including regulatory and safety consulting, which involves providing support on drug regulatory compliance; clinical feasibility consulting; and market access consulting, helping clients get their products to market faster. The company has global, regional and country-specific regulatory experts on its team who have extensive past experience in dealing with regulatory bodies worldwide.

Icon Plc's use of cutting-edge technology has contributed to its success at revolutionizing how clinical trials are conducted. The company has its own proprietary platforms, tools, and innovative technologies such as Firecrest (an e-learning platform for clinical trial management), IConnect (an intelligent patient recruitment tool) and Symphony (a clinical data management platform). Icon Plc has also implemented artificial intelligence, machine learning, and natural language processing, among other technologies, to help automate labor-intensive clinical trial processes, making more accurate and timely decisions, and saving clientse time and money.

Icon Plc's advanced analytical and laboratory services have further enhanced its position as a leading provider of clinical trials. Its labs conduct precision medicine biomarker assays, genomics, proteomics, pharmacology, and biomarker immunoassays. Icon Plc has expertise in analyzing complex molecules such as biosimilars and designing customized solutions to accommodate regulatory requirements.

In summary, Icon Plc is a global leader in clinical trials and consulting services, well-strategized to provide full-service offerings from discovery to commercialization. With its proprietary platforms and cutting-edge technologies, Icon Plc has been able to offer meticulous data-driven solutions to clients from diverse therapeutic areas. The company is committed to accelerating drug development timelines, minimizing operational costs, and providing high-quality data with its extensive worldwide team of experts.

   Company Address: South County Business Park Dublin 18 0
   Company Phone Number: 291-2000   Stock Exchange / Ticker: NASDAQ ICLR


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Icon Plc


ation: The
As the recently released financial results for the fourth quarter of 2023 earnings season showcase, Icon Plc has once again demonstrated its outstanding performance. The medical laboratories company reported a significant increase in both earnings and revenue, outpacing its sector peers and posting impressive year-over-year growth.
In terms of earnings, Icon Plc saw a remarkable increase of 20.72% to $7.40 per share, compared to $6.13 in the same period the previous year. This reflects the company's ability to efficiently manage its operations and generate higher profits. Furthermore, the net earnings of $1,236.802 million reported in the fourth quarter of 2023 were up by an astonishing 144.76% compared to the previous year. Such substantial growth speaks volumes about Icon Plc's strong financial performance.


Icon Plc's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Icon Plc does not provide revenue guidance.

Earnings Outlook
Icon Plc does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com